1 Min Read
Dec 21 (Reuters) - Mesoblast Ltd:
* U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.